Named on one round in the feed.
Since 2026-10-19
ROUNDS
1
joined, none as lead
ROUNDS JOINED · USD
$135.0M
across 1 round
CO-INVESTORS
16
named beside it
Named on one round in the feed.
Since 2026-10-19
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series D Verified against 4 of 23 sources | $135.0M | 2026-10-19 | [ PART ] |